海外战略能否复刻国内成功。《投资者网》蔡俊猝不及防间,迪哲医药(688192.SH,下称“公司”)公告多名高层的减持动向。不同于还在挣扎商业化成功的创新药同行,公司在国内已拿到一定的果实。这得益于公司在临床阶段的权威数据支撑,或者说走出了一条属于自己的路径。眼下,公司的战略在悄然改变和拓展,海外布局成了大方向。这方面,百济神州是行业成功的先例,公司能否实现海外成功,或决定自身资本价值的潜力。减持...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.